VBI Vaccines Inc. Stock

Equities

VBIV

CA91822J2020

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-05-09 EDT 5-day change 1st Jan Change
0.6033 USD +0.55% Intraday chart for VBI Vaccines Inc. +3.55% +2.69%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 14.48M 19.82M Sales 2025 * 34.12M 46.7M Capitalization 17.21M 23.55M
Net income 2024 * -42M -57.48M Net income 2025 * -25M -34.22M EV / Sales 2024 * 1.19 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.5 x
P/E ratio 2024 *
-0.43 x
P/E ratio 2025 *
-1.18 x
Employees 135
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.01%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.55%
1 week+3.55%
Current month+5.66%
1 month-8.59%
3 months-11.27%
6 months+0.53%
Current year+2.69%
More quotes
1 week
0.56
Extreme 0.5611
0.63
1 month
0.53
Extreme 0.531
0.66
Current year
0.53
Extreme 0.53
1.35
1 year
0.45
Extreme 0.45
3.47
3 years
0.45
Extreme 0.45
129.30
5 years
0.45
Extreme 0.45
207.90
10 years
0.45
Extreme 0.45
594.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 16-04-30
Director of Finance/CFO 36 15-07-08
Chief Tech/Sci/R&D Officer 54 16-05-05
Members of the board TitleAgeSince
Director/Board Member 63 23-04-23
Chairman 71 04-12-31
Chief Executive Officer 62 16-04-30
More insiders
Date Price Change Volume
24-05-09 0.6033 +0.55% 35,748
24-05-08 0.6 -0.33% 38,563
24-05-07 0.602 +0.35% 109,132
24-05-06 0.5999 +1.68% 139,988
24-05-03 0.59 +1.27% 165,340

Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm

More quotes
VBI Vaccines Inc. is a commercial stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology, The Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers, including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for corona virus disease include VBI-2901, VBI-2905, VBI-2902, and other. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2501 is its Prophylactic Candidate for Zika virus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.6033 USD
Average target price
5 USD
Spread / Average Target
+728.78%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW